Loans and Borrowings (Tables)

12 Months Ended

Dec. 31, 2020

Borrowing Costs [Abstract]

Summary of Other Loans and Borrowings

Other loans and borrowings consisted of the following:

Other loans and borrowings - Total	As of
(in € thousands)	2018/12/31		2019/12/31		2020/12/31
Refundable and conditional advances		3,229		3,229		3,229
Bank loans		3,964		2,645		1,540
Obligations under leases		1,900		12,281		10,131
Accrued interests		3		1		1
Other financial loans and borrowings		7		7		7
TOTAL		9,104		18,165		14,908
Other loans and borrowings - Current	As of
(in € thousands)	2018/12/31		2019/12/31		2020/12/31
Refundable and conditional advances		—		—		—
Bank loans		1,319		1,105		942
Obligations under leases		520		2,112		2,085
Accrued interests		3		1		1
Other financial loans and borrowings		7		7		7
TOTAL		1,848		3,226		3,035
Other loans and borrowings - Non current	As of
(in € thousands)	2018/12/31		2019/12/31		2020/12/31
Refundable and conditional advances		3,229		3,229		3,229
Bank loans		2,645		1,540		598
Obligations under leases		1,381		10,169		8,046
Accrued interests		—		—		—
Other financial loans and borrowings		—		—		—
TOTAL		7,255		14,939		11,873

Summary of Refundable and Conditional Advances

The following table summarizes advances outstanding at December 31, 2020, 2019 and 2018.

		Total								Net book value
Refundable and conditional advances - general overview	Grant	amount						Effects of		As of
(in € thousands)	date	allocated		Receipts		Repayments		discounting		2020/12/31
BPI FRANCE - IT-DIAB	12/23/2008		3,229		3,229		—		—		3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL											3,229

		Total						Net book value
Refundable and conditional advances—general overview		amount					Effects of	As of
(in thousands of euros)	Grant date	allocated		Receipts		Repayments	discounting	2019/12/31
BPI FRANCE—IT-DIAB	12/23/2008		3,229		3,229	—	—		3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL									3,229

		Total						Net book value
Refundable and conditional advances—general overview		amount					Effects of	As of
(in € thousands)	Grant date	allocated		Receipts		Repayments	discounting	2018/12/31
BPI FRANCE—IT-DIAB	12/23/2008		3,229		3,229	—	—		3,229
Development of a global strategy for the prevention and management of type 2 diabetes
TOTAL									3,407

Summary of Bank Loans

Bank loans are primarily used to finance research and laboratory equipment. Bank loans consisted of the following as of December 31, 2018:

							Available			Outstanding
Bank loans	Loan	Facility		Interest			As of			As of
(in € thousands)	date	size		rate			2018/12/31		Installments	2018/12/31
CDN 5	November 2018		500		0.46	%		—	48 monthly		490
CIC 5	July 2017		1,000		0.69	%		—	60 monthly		753
CDN 4	June 2017		600		0.36	%		—	48 monthly		376
BNP 4	April 2017		800		0.87	%		—	60 monthly		695
CIC 4	December 2016		265		0.69	%		—	60 monthly		164
BNP 3	October 2016		1,050		0.80	%		—	20 quarterly		735
NEUFLIZE 2	June 2016		500		1.10	%		—	12 quarterly		84
BNP 2	June 2016		500		0.80	%		—	20 quarterly		277
CDN 3	April 2016		500		0.72	%		—	60 monthly		236
CIC 3	March 2015		500		0.85	%		—	16 quarterly		32
BNP	December 2014		500		2.00	%		—	20 quarterly		103
Other			—					—			19
TOTAL			6,715								3,964

Bank loans consisted of the following as of December 31, 2019:

							Available			Outstanding
Bank loans	Loan	Facility		Interest			As of			As of
(in € thousands)	date	size		rate			2019/12/31		Installments	2019/12/31
CDN 5	November 2018		500		0.00	%		—	48 monthly		365
CIC 5	July 2017	1000			0.00	%	0		60 monthly		554
CDN 4	June 2017	600			0.00	%	0		48 monthly		226
BNP 4	April 2017	800			0.00	%	0		60 monthly		537
CIC 4	December 2016		265		0.00	%		—	60 monthly		111
BNP 3	October 2016	1050			0.00	%	0		20 quarterly		525
NEUFLIZE 2	June 2016	500			0.00	%	0		12 quarterly		0
BNP 2	June 2016	500			0.00	%	0		20 quarterly		177
CDN 3	April 2016		500		0.00	%		—	60 monthly		135
CIC 3	March 2015	500			0.00	%	0		16 quarterly		0
BNP	December 2014	500			0.00	%	0		20 quarterly		0
Other		0					0				14
TOTAL			6,715								2,645

Bank loans consisted of the following as of December 31, 2020:

							Available			Outstanding
Bank loans	Loan	Facility		Interest			As of			As of
(in € thousands)	date	size		rate			2020/12/31		Installments	2020/12/31
CDN 5	November 2018		500		0.00	%		—	48 monthly		241
CIC 5	July 2017	1000			0.00	%	0		60 monthly		354
CDN 4	June 2017	600			0.00	%	0		48 monthly		75
BNP 4	April 2017	800			0.00	%	0		60 monthly		377
CIC 4	December 2016		265		0.00	%		—	60 monthly		58
BNP 3	October 2016	1050			0.00	%	0		20 quarterly		315
NEUFLIZE 2	June 2016	500			0.00	%	0		12 quarterly		0
BNP 2	June 2016	500			0.00	%	0		20 quarterly		76
CDN 3	April 2016		500		0.00	%		—	60 monthly		34
CIC 3	March 2015	500			0.00	%	0		16 quarterly		0
BNP	December 2014	500			0.00	%	0		20 quarterly		0
Other		0					0				9
TOTAL			6,715					—			1,540

Summary of Maturities of Financial Liabilities

Maturity of financial liabilities	As of		Less than		Less than		Less than		Less than		Less than		More than
(in € thousands)	2020/12/31		1 year		2 years		3 years		4 years		5 years		5 years
BPI FRANCE - IT-DIAB		3,229		—		—		—		—		—		3,229
TOTAL - Refundable and conditional advances		3,229		—		—		—		—		—		3,229
Convertible loans		170,782		1,313		169,470		—		—		—		—
Bank loans		1,540		942		544		54		—		—		—
Leases		10,131		2,085		1,564		1,150		1,109		1,039		3,184
Accrued interests		1		1		—		—		—		—		—
Other financial loans and borrowings		7		7		—		—		—		—		—
TOTAL - Other loans and borrowings		182,461		4,348		171,577		1,205		1,109		1,039		3,184
TOTAL		185,691		4,348		171,577		1,205		1,109		1,039		6,413

Under the initial terms, the convertible bond results in the payment of yearly interest of €6,300 and a reimbursement at par in October 2022. The nominal amount of the convertible loan of €180 million is due in less than 2 years. Regarding the renegotiation of this bond debt, please see Note 2.2 “Renegotiation of the convertible bond debt (OCEANEs)”.

Regarding the IT-DIAB advance, please see Note 12.2.1 “Refundable and conditional advances”.